Global Latex Agglutination Test Kits Market By Test Type( Bacterial Antigen test, Blood & Serum test, Staphylococcus aureus test, Legionella pneumophila test, E. coli Latex test, Others) By Disease Indication( Pneumococcal infection, Hemophilus influenzae type b (Hib), Rubella, Others) By End Users( Hospitals, Diagnostic Centers, Specialty Clinics, Others) By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
In the last few years, there has been a rise in various types of diseases which has led to the adoption of different type of testing methods to determine accurate results within less time. Latex agglutination testing method is gaining huge popularity due to its simplicity in testing methods and shorter time for results. Agglutination is the process of mixing an antigen with its corresponding antibody, agglutinin, which is often employed in blood grouping. Latex agglutination testing, commonly known as latex fixation, is a diagnostic procedure for identifying specific antibodies and antigens in the laboratory. Blood, urine, saliva, and cerebrospinal fluid are among the body fluids used in the test, depending on the type of sample required. In latex agglutination testing, a sample containing the appropriate antigen or antibody is collected, then mixed with an antibody or antigen coated on latex beads in serial dilutions with normal saline. The latex beads will cluster together if the suspected drug is present. A latex fixation test can be performed for the serologic diagnosis of rheumatoid arthritis, a long-term autoimmune illness that causes pain, swelling, and stiffness in the joints and many other diseases. In terms of revenue, global latex agglutination test kits market was valued at US$ 3,481.23 Mn in 2021 growing at a CAGR of 7.9% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Test Type Outlook:
Based on the test type, the market is segmented into bacterial antigen test, blood & serum test, staphylococcus aureus test, legionella pneumophila test, E. coli latex test and others. The bacteria E. coli (Escherichia coli) ordinarily lives in the intestines of humans. The majority of E. coli strains are safe and even beneficial to our digestive system's health. However, if humans eat contaminated food or drink polluted water, some strains can induce diarrhoea. According to research studies, E. coli is accountable for 75 to 95 percent of urinary tract diseases. O157:H7 is a particularly dangerous strain that can make humans very sick. Abdominal cramps, vomiting, and bloody diarrhoea are all symptoms that are the most common reason for acute renal failure. There has been an increasing number of outbreaks associated with E.coli O157:H7 due to contaminated foods. Thus, to detect these E.coli bacteria the demand for latex agglutination test kits market rose globally.
Global Latex Agglutination Test Kits Market Revenue & Forecast, (US$ Million), 2015 – 2030
Disease Indication Outlook:
Based on disease indication, the latex agglutination test kits market is segmented into pneumococcal infection, hemophilus influenzae type b (Hib), rubella and others. Rubella is a common childhood virus that can have serious repercussions for infants who are infected before birth. Infected women commonly spread the illness to their foetus during the first 16 weeks of pregnancy (especially the first 8 to 10 weeks). Rubella was once known as "German measles" or "three-day measles" because it develops a rash that resembles that of measles. It is, however, brought on by a distinct infection. In the last few years due to the availability of an attenuated rubella virus vaccination, the natural occurrence of rubella infection has decreased dramatically. Nonetheless, all women of reproductive age should be screened for the presence of rubella antibodies to ensure that nonimmune individuals are identified and vaccinated. Latex agglutination test is considered to be effective for the qualitative and semiquantitative determination of rubella virus antibodies in serum. The method of testing antibodies of the rubella virus can be measured in blood, or samples from the throat, nose, or urine can be tested to confirm the rubella diagnosis. During the test the antigen-antibody reaction can be observed visually owing to latex particles. When rubella virus antibodies are added to the latex reagent, the uniform look of the latex suspension transforms into visible agglutination giving accurate results within less time. Thus, latex agglutination test kits market is gaining importance globally owing to their effective and accurate results.
Region Outlook:
Based on the regions, North America had the highest share in the latex agglutination test kits market in the year 2021. In the last few years there has been a rise in the diagnosis and testing of various diseases in United States and Canada. For instance, the rising concern of hepatitis B virus infection amongst a huge population has led to increased demand for latex agglutination test kits for effective diagnosis and results for better treatments. Moreover, hospitals and diagnostic centers are readily looking forward to invest into latex agglutination test kits for treating various diseases effectively. Furthermore, flexible regional government policies are encouraging the use of latex agglutination tests to provide treatments for infectious diseases which is further increasing its demand. Additionally the huge presence of the leading players in North America has proven to be advantageous due to readily available test kits which is boosting the latex agglutination test kits market.
Competitive Landscape
The report provides both, qualitative and quantitative research of global latex agglutination test kits market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global latex agglutination test kits market are
- Alpha Laboratories
- Arlington Scientific, Inc
- Atlas Medical GmbH
- Bio-Rad Laboratories, Inc
- Biotec
- Hardy Diagnostics
- Henry Schein, Inc
- HiMedia Laboratories
- Lab M Limited
- Lorne Laboratories Limited
- Microgen
- Ngaio Diagnostics,
- Plasmatec
- Pro Lab Diagnostics Inc.
- Thermo Fisher Scientific Inc
- Torax Biosciences Limited
- Trafalgar Scientific Ltd
- Other Market Participants
Global Latex Agglutination Test Kits Market:
By Test Type
- Bacterial Antigen test
- Blood & Serum test
- Staphylococcus aureus test
- Legionella pneumophila test
- coli Latex test
- Others
By Disease Indication
- Pneumococcal infection
- Hemophilus influenzae type b (Hib)
- Rubella
- Others
By End Users
- Hospitals
- Diagnostic Centers
- Specialty
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Latex Agglutination Test Kits Market
6.
Market
Synopsis: Latex Agglutination Test Kits
Market
7.
Latex
Agglutination Test Kits Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Latex Agglutination Test Kits
Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Latex Agglutination Test Kits Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Latex Agglutination
Test Kits Market
8.
Global Latex
Agglutination Test Kits Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Latex Agglutination Test Kits Market
Revenue (US$ Mn)
8.2. Global Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
8.2.1. Bacterial Antigen test
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 – 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 – 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 – 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 – 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 – 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 – 2030
8.2.2. Blood and Serum test
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 – 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 – 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 – 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 – 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 – 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 – 2030
8.2.3. Staphylococcus aureus test
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.3.3.
Market
Forecast, 2022 – 2030
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North America
8.2.3.5.1.1. Market Estimation, 2015 - 2021
8.2.3.5.1.2. Market Forecast, 2022 – 2030
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2021
8.2.3.5.2.2. Market Forecast, 2022 – 2030
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2021
8.2.3.5.3.2. Market Forecast, 2022 – 2030
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2021
8.2.3.5.4.2. Market Forecast, 2022 – 2030
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2021
8.2.3.5.5.2. Market Forecast, 2022 – 2030
8.2.4. Legionella pneumophila test
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.4.3.
Market
Forecast, 2022 – 2030
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2021
8.2.4.5.1.2. Market Forecast, 2022 – 2030
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2021
8.2.4.5.2.2. Market Forecast, 2022 – 2030
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2021
8.2.4.5.3.2. Market Forecast, 2022 – 2030
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2021
8.2.4.5.4.2. Market Forecast, 2022 – 2030
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2021
8.2.4.5.5.2. Market Forecast, 2022 – 2030
8.2.5. E. coli Latex test
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.5.3.
Market
Forecast, 2022 – 2030
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1.
North
America
8.2.5.5.1.1. Market Estimation, 2015 - 2021
8.2.5.5.1.2. Market Forecast, 2022 – 2030
8.2.5.5.2.
Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2021
8.2.5.5.2.2. Market Forecast, 2022 – 2030
8.2.5.5.3.
Asia
Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2021
8.2.5.5.3.2. Market Forecast, 2022 – 2030
8.2.5.5.4.
Middle
East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2021
8.2.5.5.4.2. Market Forecast, 2022 – 2030
8.2.5.5.5.
Latin
America
8.2.5.5.5.1. Market Estimation, 2015 - 2021
8.2.5.5.5.2. Market Forecast, 2022 – 2030
8.2.6. Others
8.2.6.1.
Definition
8.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.6.3.
Market
Forecast, 2022 – 2030
8.2.6.4.
Compound
Annual Growth Rate (CAGR)
8.2.6.5.
Regional
Bifurcation
8.2.6.5.1.
North
America
8.2.6.5.1.1. Market Estimation, 2015 - 2021
8.2.6.5.1.2. Market Forecast, 2022 – 2030
8.2.6.5.2.
Europe
8.2.6.5.2.1. Market Estimation, 2015 - 2021
8.2.6.5.2.2. Market Forecast, 2022 – 2030
8.2.6.5.3.
Asia
Pacific
8.2.6.5.3.1. Market Estimation, 2015 - 2021
8.2.6.5.3.2. Market Forecast, 2022 – 2030
8.2.6.5.4.
Middle
East and Africa
8.2.6.5.4.1. Market Estimation, 2015 - 2021
8.2.6.5.4.2. Market Forecast, 2022 – 2030
8.2.6.5.5.
Latin
America
8.2.6.5.5.1. Market Estimation, 2015 - 2021
8.2.6.5.5.2. Market Forecast, 2022 – 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Test Type
9.
Global Latex
Agglutination Test Kits Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
9.2.1. Pneumococcal infection
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 – 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 – 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 – 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 – 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 – 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 – 2030
9.2.2. Hemophilus influenzae type b (Hib)
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 – 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 – 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 – 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 – 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 – 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 – 2030
9.2.3. Rubella
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.3.3.
Market
Forecast, 2022 – 2030
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2021
9.2.3.5.1.2. Market Forecast, 2022 – 2030
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2021
9.2.3.5.2.2. Market Forecast, 2022 – 2030
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2021
9.2.3.5.3.2. Market Forecast, 2022 – 2030
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2021
9.2.3.5.4.2. Market Forecast, 2022 – 2030
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2021
9.2.3.5.5.2. Market Forecast, 2022 – 2030
9.2.4. Others
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.4.3.
Market
Forecast, 2022 – 2030
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2021
9.2.4.5.1.2. Market Forecast, 2022 – 2030
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2021
9.2.4.5.2.2. Market Forecast, 2022 – 2030
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2021
9.2.4.5.3.2. Market Forecast, 2022 – 2030
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2021
9.2.4.5.4.2. Market Forecast, 2022 – 2030
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2021
9.2.4.5.5.2. Market Forecast, 2022 – 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Disease Indication
10. Global Latex Agglutination Test Kits Market
Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
10.2.1. Hospitals
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 -
2021
10.2.1.3. Market Forecast, 2022 – 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 – 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 – 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 – 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 – 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 – 2030
10.2.2. Diagnostic Centers
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 -
2021
10.2.2.3. Market Forecast, 2022 – 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 – 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 – 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 – 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 – 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 – 2030
10.2.3. Specialty Clinics
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 -
2021
10.2.3.3. Market Forecast, 2022 – 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 - 2021
10.2.3.5.1.2. Market Forecast, 2022 – 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2021
10.2.3.5.2.2. Market Forecast, 2022 – 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2021
10.2.3.5.3.2. Market Forecast, 2022 – 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2021
10.2.3.5.4.2. Market Forecast, 2022 – 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 - 2021
10.2.3.5.5.2. Market Forecast, 2022 – 2030
10.2.4. Others
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 -
2021
10.2.4.3. Market Forecast, 2022 – 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market Estimation, 2015 - 2021
10.2.4.5.1.2. Market Forecast, 2022 – 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market Estimation, 2015 - 2021
10.2.4.5.2.2. Market Forecast, 2022 – 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market Estimation, 2015 - 2021
10.2.4.5.3.2. Market Forecast, 2022 – 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market Estimation, 2015 - 2021
10.2.4.5.4.2. Market Forecast, 2022 – 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market Estimation, 2015 - 2021
10.2.4.5.5.2. Market Forecast, 2022 – 2030
10.3. Key Segment for Channeling Investments
10.3.1. By End Users
11. North America Latex Agglutination Test Kits
Market Analysis and Forecasts, 2022 – 2030
11.1. Overview
11.1.1. North America Latex Agglutination Test Kits
Market Revenue (US$ Mn)
11.2. North America Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Test Type
11.2.1. Bacterial Antigen test
11.2.2. Blood and Serum test
11.2.3. Staphylococcus aureus test
11.2.4. Legionella pneumophila test
11.2.5. E. coli Latex test
11.2.6. Others
11.3. North America Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
11.3.1. Pneumococcal infection
11.3.2. Hemophilus influenzae type b (Hib)
11.3.3. Rubella
11.3.4. Others
11.4. North America Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By End Users
11.4.1. Hospitals
11.4.2. Diagnostic Centers
11.4.3. Specialty Clinics
11.4.4. Others
11.5. North America Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
11.5.1.1.1. Bacterial Antigen test
11.5.1.1.2. Blood and Serum test
11.5.1.1.3. Staphylococcus aureus test
11.5.1.1.4. Legionella pneumophila test
11.5.1.1.5. E. coli Latex test
11.5.1.1.6. Others
11.5.1.2. U.S Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
11.5.1.2.1. Pneumococcal infection
11.5.1.2.2. Hemophilus influenzae type b (Hib)
11.5.1.2.3. Rubella
11.5.1.2.4. Others
11.5.1.3. U.S Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
11.5.1.3.1. Hospitals
11.5.1.3.2. Diagnostic Centers
11.5.1.3.3. Specialty Clinics
11.5.1.3.4. Others
11.5.2. Canada
11.5.2.1. Canada Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
11.5.2.1.1. Bacterial Antigen test
11.5.2.1.2. Blood and Serum test
11.5.2.1.3. Staphylococcus aureus test
11.5.2.1.4. Legionella pneumophila test
11.5.2.1.5. E. coli Latex test
11.5.2.1.6. Others
11.5.2.2. Canada Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
11.5.2.2.1. Pneumococcal infection
11.5.2.2.2. Hemophilus influenzae type b (Hib)
11.5.2.2.3. Rubella
11.5.2.2.4. Others
11.5.2.3. Canada Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
11.5.2.3.1. Hospitals
11.5.2.3.2. Diagnostic Centers
11.5.2.3.3. Specialty Clinics
11.5.2.3.4. Others
11.5.3. Mexico
11.5.3.1. Mexico Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
11.5.3.1.1. Bacterial Antigen test
11.5.3.1.2. Blood and Serum test
11.5.3.1.3. Staphylococcus aureus test
11.5.3.1.4. Legionella pneumophila test
11.5.3.1.5. E. coli Latex test
11.5.3.1.6. Others
11.5.3.2. Mexico Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
11.5.3.2.1. Pneumococcal infection
11.5.3.2.2. Hemophilus influenzae type b (Hib)
11.5.3.2.3. Rubella
11.5.3.2.4. Others
11.5.3.3. Mexico Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
11.5.3.3.1. Hospitals
11.5.3.3.2. Diagnostic Centers
11.5.3.3.3. Specialty Clinics
11.5.3.3.4. Others
11.5.4. Rest of North America
11.5.4.1. Rest of North America Latex Agglutination
Test Kits Market Revenue (US$ Mn) and Forecasts, By Test Type
11.5.4.1.1. Bacterial Antigen test
11.5.4.1.2. Blood and Serum test
11.5.4.1.3. Staphylococcus aureus test
11.5.4.1.4. Legionella pneumophila test
11.5.4.1.5. E. coli Latex test
11.5.4.1.6. Others
11.5.4.2. Rest of North America Latex Agglutination
Test Kits Market Revenue (US$ Mn) and Forecasts, By Disease Indication
11.5.4.2.1. Pneumococcal infection
11.5.4.2.2. Hemophilus influenzae type b (Hib)
11.5.4.2.3. Rubella
11.5.4.2.4. Others
11.5.4.3. Rest of North America Latex Agglutination
Test Kits Market Revenue (US$ Mn) and Forecasts, By End Users
11.5.4.3.1. Hospitals
11.5.4.3.2. Diagnostic Centers
11.5.4.3.3. Specialty Clinics
11.5.4.3.4. Others
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By Test Type
11.6.3. By Disease Indication
11.6.4. By End Users
12. Europe Latex Agglutination Test Kits Market
Analysis and Forecasts, 2022 – 2030
12.1. Overview
12.1.1. Europe Latex Agglutination Test Kits Market
Revenue (US$ Mn)
12.2. Europe Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
12.2.1. Bacterial Antigen test
12.2.2. Blood and Serum test
12.2.3. Staphylococcus aureus test
12.2.4. Legionella pneumophila test
12.2.5. E. coli Latex test
12.2.6. Others
12.3. Europe Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
12.3.1. Pneumococcal infection
12.3.2. Hemophilus influenzae type b (Hib)
12.3.3. Rubella
12.3.4. Others
12.4. Europe Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
12.4.1. Hospitals
12.4.2. Diagnostic Centers
12.4.3. Specialty Clinics
12.4.4. Others
12.5. Europe Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
12.5.1.1.1. Bacterial Antigen test
12.5.1.1.2. Blood and Serum test
12.5.1.1.3. Staphylococcus aureus test
12.5.1.1.4. Legionella pneumophila test
12.5.1.1.5. E. coli Latex test
12.5.1.1.6. Others
12.5.1.2. France Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
12.5.1.2.1. Pneumococcal infection
12.5.1.2.2. Hemophilus influenzae type b (Hib)
12.5.1.2.3. Rubella
12.5.1.2.4. Others
12.5.1.3. France Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
12.5.1.3.1. Hospitals
12.5.1.3.2. Diagnostic Centers
12.5.1.3.3. Specialty Clinics
12.5.1.3.4. Others
12.5.2. The UK
12.5.2.1. The UK Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
12.5.2.1.1. Bacterial Antigen test
12.5.2.1.2. Blood and Serum test
12.5.2.1.3. Staphylococcus aureus test
12.5.2.1.4. Legionella pneumophila test
12.5.2.1.5. E. coli Latex test
12.5.2.1.6. Others
12.5.2.2. The UK Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
12.5.2.2.1. Pneumococcal infection
12.5.2.2.2. Hemophilus influenzae type b (Hib)
12.5.2.2.3. Rubella
12.5.2.2.4. Others
12.5.2.3. The UK Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
12.5.2.3.1. Hospitals
12.5.2.3.2. Diagnostic Centers
12.5.2.3.3. Specialty Clinics
12.5.2.3.4. Others
12.5.3. Spain
12.5.3.1. Spain Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
12.5.3.1.1. Bacterial Antigen test
12.5.3.1.2. Blood and Serum test
12.5.3.1.3. Staphylococcus aureus test
12.5.3.1.4. Legionella pneumophila test
12.5.3.1.5. E. coli Latex test
12.5.3.1.6. Others
12.5.3.2. Spain Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
12.5.3.2.1. Pneumococcal infection
12.5.3.2.2. Hemophilus influenzae type b (Hib)
12.5.3.2.3. Rubella
12.5.3.2.4. Others
12.5.3.3. Spain Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
12.5.3.3.1. Hospitals
12.5.3.3.2. Diagnostic Centers
12.5.3.3.3. Specialty Clinics
12.5.3.3.4. Others
12.5.4. Germany
12.5.4.1. Germany Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
12.5.4.1.1. Bacterial Antigen test
12.5.4.1.2. Blood and Serum test
12.5.4.1.3. Staphylococcus aureus test
12.5.4.1.4. Legionella pneumophila test
12.5.4.1.5. E. coli Latex test
12.5.4.1.6. Others
12.5.4.2. Germany Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
12.5.4.2.1. Pneumococcal infection
12.5.4.2.2. Hemophilus influenzae type b (Hib)
12.5.4.2.3. Rubella
12.5.4.2.4. Others
12.5.4.3. Germany Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
12.5.4.3.1. Hospitals
12.5.4.3.2. Diagnostic Centers
12.5.4.3.3. Specialty Clinics
12.5.4.3.4. Others
12.5.5. Italy
12.5.5.1. Italy Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
12.5.5.1.1. Bacterial Antigen test
12.5.5.1.2. Blood and Serum test
12.5.5.1.3. Staphylococcus aureus test
12.5.5.1.4. Legionella pneumophila test
12.5.5.1.5. E. coli Latex test
12.5.5.1.6. Others
12.5.5.2. Italy Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
12.5.5.2.1. Pneumococcal infection
12.5.5.2.2. Hemophilus influenzae type b (Hib)
12.5.5.2.3. Rubella
12.5.5.2.4. Others
12.5.5.3. Italy Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
12.5.5.3.1. Hospitals
12.5.5.3.2. Diagnostic Centers
12.5.5.3.3. Specialty Clinics
12.5.5.3.4. Others
12.5.6. Nordic Countries
12.5.6.1. Nordic Countries Latex Agglutination Test
Kits Market Revenue (US$ Mn) and Forecasts, By Test Type
12.5.6.1.1. Bacterial Antigen test
12.5.6.1.2. Blood and Serum test
12.5.6.1.3. Staphylococcus aureus test
12.5.6.1.4. Legionella pneumophila test
12.5.6.1.5. E. coli Latex test
12.5.6.1.6. Others
12.5.6.2. Nordic Countries Latex Agglutination Test
Kits Market Revenue (US$ Mn) and Forecasts, By Disease Indication
12.5.6.2.1. Pneumococcal infection
12.5.6.2.2. Hemophilus influenzae type b (Hib)
12.5.6.2.3. Rubella
12.5.6.2.4. Others
12.5.6.3. Nordic Countries Latex Agglutination Test
Kits Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.6.3.1. Hospitals
12.5.6.3.2. Diagnostic Centers
12.5.6.3.3. Specialty Clinics
12.5.6.3.4. Others
12.5.6.4. Nordic Countries Latex Agglutination Test
Kits Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux Union
12.5.7.1. Benelux Union Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
12.5.7.1.1. Bacterial Antigen test
12.5.7.1.2. Blood and Serum test
12.5.7.1.3. Staphylococcus aureus test
12.5.7.1.4. Legionella pneumophila test
12.5.7.1.5. E. coli Latex test
12.5.7.1.6. Others
12.5.7.2. Benelux Union Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
12.5.7.2.1. Pneumococcal infection
12.5.7.2.2. Hemophilus influenzae type b (Hib)
12.5.7.2.3. Rubella
12.5.7.2.4. Others
12.5.7.3. Benelux Union Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.7.3.1. Hospitals
12.5.7.3.2. Diagnostic Centers
12.5.7.3.3. Specialty Clinics
12.5.7.3.4. Others
12.5.7.4. Benelux Union Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of Europe
12.5.8.1. Rest of Europe Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Test Type
12.5.8.1.1. Bacterial Antigen test
12.5.8.1.2. Blood and Serum test
12.5.8.1.3. Staphylococcus aureus test
12.5.8.1.4. Legionella pneumophila test
12.5.8.1.5. E. coli Latex test
12.5.8.1.6. Others
12.5.8.2. Rest of Europe Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
12.5.8.2.1. Pneumococcal infection
12.5.8.2.2. Hemophilus influenzae type b (Hib)
12.5.8.2.3. Rubella
12.5.8.2.4. Others
12.5.8.3. Rest of Europe Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.8.3.1. Hospitals
12.5.8.3.2. Diagnostic Centers
12.5.8.3.3. Specialty Clinics
12.5.8.3.4. Others
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By Test Type
12.6.3. By Disease Indication
12.6.4. By End Users
13. Asia Pacific Latex Agglutination Test Kits
Market Analysis and Forecasts, 2022 – 2030
13.1. Overview
13.1.1. Asia Pacific Latex Agglutination Test Kits
Market Revenue (US$ Mn)
13.2. Asia Pacific Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Test Type
13.2.1. Bacterial Antigen test
13.2.2. Blood and Serum test
13.2.3. Staphylococcus aureus test
13.2.4. Legionella pneumophila test
13.2.5. E. coli Latex test
13.2.6. Others
13.3. Asia Pacific Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.3.1. Pneumococcal infection
13.3.2. Hemophilus influenzae type b (Hib)
13.3.3. Rubella
13.3.4. Others
13.4. Asia Pacific Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By End Users
13.4.1. Hospitals
13.4.2. Diagnostic Centers
13.4.3. Specialty Clinics
13.4.4. Others
13.5. Asia Pacific Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
13.5.1.1.1. Bacterial Antigen test
13.5.1.1.2. Blood and Serum test
13.5.1.1.3. Staphylococcus aureus test
13.5.1.1.4. Legionella pneumophila test
13.5.1.1.5. E. coli Latex test
13.5.1.1.6. Others
13.5.1.2. China Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
13.5.1.2.1. Pneumococcal infection
13.5.1.2.2. Hemophilus influenzae type b (Hib)
13.5.1.2.3. Rubella
13.5.1.2.4. Others
13.5.1.3. China Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
13.5.1.3.1. Hospitals
13.5.1.3.2. Diagnostic Centers
13.5.1.3.3. Specialty Clinics
13.5.1.3.4. Others
13.5.2. Japan
13.5.2.1. Japan Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
13.5.2.1.1. Bacterial Antigen test
13.5.2.1.2. Blood and Serum test
13.5.2.1.3. Staphylococcus aureus test
13.5.2.1.4. Legionella pneumophila test
13.5.2.1.5. E. coli Latex test
13.5.2.1.6. Others
13.5.2.2. Japan Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
13.5.2.2.1. Pneumococcal infection
13.5.2.2.2. Hemophilus influenzae type b (Hib)
13.5.2.2.3. Rubella
13.5.2.2.4. Others
13.5.2.3. Japan Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
13.5.2.3.1. Hospitals
13.5.2.3.2. Diagnostic Centers
13.5.2.3.3. Specialty Clinics
13.5.2.3.4. Others
13.5.3. India
13.5.3.1. India Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
13.5.3.1.1. Bacterial Antigen test
13.5.3.1.2. Blood and Serum test
13.5.3.1.3. Staphylococcus aureus test
13.5.3.1.4. Legionella pneumophila test
13.5.3.1.5. E. coli Latex test
13.5.3.1.6. Others
13.5.3.2. India Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
13.5.3.2.1. Pneumococcal infection
13.5.3.2.2. Hemophilus influenzae type b (Hib)
13.5.3.2.3. Rubella
13.5.3.2.4. Others
13.5.3.3. India Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
13.5.3.3.1. Hospitals
13.5.3.3.2. Diagnostic Centers
13.5.3.3.3. Specialty Clinics
13.5.3.3.4. Others
13.5.4. New Zealand
13.5.4.1. New Zealand Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Test Type
13.5.4.1.1. Bacterial Antigen test
13.5.4.1.2. Blood and Serum test
13.5.4.1.3. Staphylococcus aureus test
13.5.4.1.4. Legionella pneumophila test
13.5.4.1.5. E. coli Latex test
13.5.4.1.6. Others
13.5.4.2. New Zealand Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.5.4.2.1. Pneumococcal infection
13.5.4.2.2. Hemophilus influenzae type b (Hib)
13.5.4.2.3. Rubella
13.5.4.2.4. Others
13.5.4.3. New Zealand Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.4.3.1. Hospitals
13.5.4.3.2. Diagnostic Centers
13.5.4.3.3. Specialty Clinics
13.5.4.3.4. Others
13.5.5. Australia
13.5.5.1. Australia Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Test Type
13.5.5.1.1. Bacterial Antigen test
13.5.5.1.2. Blood and Serum test
13.5.5.1.3. Staphylococcus aureus test
13.5.5.1.4. Legionella pneumophila test
13.5.5.1.5. E. coli Latex test
13.5.5.1.6. Others
13.5.5.2. Australia Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.5.5.2.1. Pneumococcal infection
13.5.5.2.2. Hemophilus influenzae type b (Hib)
13.5.5.2.3. Rubella
13.5.5.2.4. Others
13.5.5.3. Australia Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.5.3.1. Hospitals
13.5.5.3.2. Diagnostic Centers
13.5.5.3.3. Specialty Clinics
13.5.5.3.4. Others
13.5.6. South Korea
13.5.6.1. South Korea Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Test Type
13.5.6.1.1. Bacterial Antigen test
13.5.6.1.2. Blood and Serum test
13.5.6.1.3. Staphylococcus aureus test
13.5.6.1.4. Legionella pneumophila test
13.5.6.1.5. E. coli Latex test
13.5.6.1.6. Others
13.5.6.2. South Korea Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.5.6.2.1. Pneumococcal infection
13.5.6.2.2. Hemophilus influenzae type b (Hib)
13.5.6.2.3. Rubella
13.5.6.2.4. Others
13.5.6.3. South Korea Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.6.3.1. Hospitals
13.5.6.3.2. Diagnostic Centers
13.5.6.3.3. Specialty Clinics
13.5.6.3.4. Others
13.5.7. Southeast Asia
13.5.7.1. Southeast Asia Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Test Type
13.5.7.1.1. Bacterial Antigen test
13.5.7.1.2. Blood and Serum test
13.5.7.1.3. Staphylococcus aureus test
13.5.7.1.4. Legionella pneumophila test
13.5.7.1.5. E. coli Latex test
13.5.7.1.6. Others
13.5.7.2. Southeast Asia Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.5.7.2.1. Pneumococcal infection
13.5.7.2.2. Hemophilus influenzae type b (Hib)
13.5.7.2.3. Rubella
13.5.7.2.4. Others
13.5.7.3. Southeast Asia Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.7.3.1. Hospitals
13.5.7.3.2. Diagnostic Centers
13.5.7.3.3. Specialty Clinics
13.5.7.3.4. Others
13.5.7.4. Southeast Asia Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1. Rest of Asia Pacific Latex Agglutination Test
Kits Market Revenue (US$ Mn) and Forecasts, By Test Type
13.5.8.1.1. Bacterial Antigen test
13.5.8.1.2. Blood and Serum test
13.5.8.1.3. Staphylococcus aureus test
13.5.8.1.4. Legionella pneumophila test
13.5.8.1.5. E. coli Latex test
13.5.8.1.6. Others
13.5.8.2. Rest of Asia Pacific Latex Agglutination Test
Kits Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.5.8.2.1. Pneumococcal infection
13.5.8.2.2. Hemophilus influenzae type b (Hib)
13.5.8.2.3. Rubella
13.5.8.2.4. Others
13.5.8.3. Rest of Asia Pacific Latex Agglutination Test
Kits Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.8.3.1. Hospitals
13.5.8.3.2. Diagnostic Centers
13.5.8.3.3. Specialty Clinics
13.5.8.3.4. Others
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By Test Type
13.6.3. By Disease Indication
13.6.4. By End Users
14. Middle East and Africa Latex Agglutination
Test Kits Market Analysis and Forecasts, 2022 – 2030
14.1. Overview
14.1.1. Middle East and Africa Latex Agglutination
Test Kits Market Revenue (US$ Mn)
14.2. Middle East and Africa Latex Agglutination
Test Kits Market Revenue (US$ Mn) and Forecasts, By Test Type
14.2.1. Bacterial Antigen test
14.2.2. Blood and Serum test
14.2.3. Staphylococcus aureus test
14.2.4. Legionella pneumophila test
14.2.5. E. coli Latex test
14.2.6. Others
14.3. Middle East and Africa Latex Agglutination
Test Kits Market Revenue (US$ Mn) and Forecasts, By Disease Indication
14.3.1. Pneumococcal infection
14.3.2. Hemophilus influenzae type b (Hib)
14.3.3. Rubella
14.3.4. Others
14.4. Middle East and Africa Latex Agglutination
Test Kits Market Revenue (US$ Mn) and Forecasts, By End Users
14.4.1. Hospitals
14.4.2. Diagnostic Centers
14.4.3. Specialty Clinics
14.4.4. Others
14.5. Middle East and Africa Latex Agglutination
Test Kits Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1. Saudi Arabia Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Test Type
14.5.1.1.1. Bacterial Antigen test
14.5.1.1.2. Blood and Serum test
14.5.1.1.3. Staphylococcus aureus test
14.5.1.1.4. Legionella pneumophila test
14.5.1.1.5. E. coli Latex test
14.5.1.1.6. Others
14.5.1.2. Saudi Arabia Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
14.5.1.2.1. Pneumococcal infection
14.5.1.2.2. Hemophilus influenzae type b (Hib)
14.5.1.2.3. Rubella
14.5.1.2.4. Others
14.5.1.3. Saudi Arabia Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.1.3.1. Hospitals
14.5.1.3.2. Diagnostic Centers
14.5.1.3.3. Specialty Clinics
14.5.1.3.4. Others
14.5.2. UAE
14.5.2.1. UAE Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
14.5.2.1.1. Bacterial Antigen test
14.5.2.1.2. Blood and Serum test
14.5.2.1.3. Staphylococcus aureus test
14.5.2.1.4. Legionella pneumophila test
14.5.2.1.5. E. coli Latex test
14.5.2.1.6. Others
14.5.2.2. UAE Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
14.5.2.2.1. Pneumococcal infection
14.5.2.2.2. Hemophilus influenzae type b (Hib)
14.5.2.2.3. Rubella
14.5.2.2.4. Others
14.5.2.3. UAE Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
14.5.2.3.1. Hospitals
14.5.2.3.2. Diagnostic Centers
14.5.2.3.3. Specialty Clinics
14.5.2.3.4. Others
14.5.3. Egypt
14.5.3.1. Egypt Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
14.5.3.1.1. Bacterial Antigen test
14.5.3.1.2. Blood and Serum test
14.5.3.1.3. Staphylococcus aureus test
14.5.3.1.4. Legionella pneumophila test
14.5.3.1.5. E. coli Latex test
14.5.3.1.6. Others
14.5.3.2. Egypt Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
14.5.3.2.1. Pneumococcal infection
14.5.3.2.2. Hemophilus influenzae type b (Hib)
14.5.3.2.3. Rubella
14.5.3.2.4. Others
14.5.3.3. Egypt Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
14.5.3.3.1. Hospitals
14.5.3.3.2. Diagnostic Centers
14.5.3.3.3. Specialty Clinics
14.5.3.3.4. Others
14.5.4. Kuwait
14.5.4.1. Kuwait Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
14.5.4.1.1. Bacterial Antigen test
14.5.4.1.2. Blood and Serum test
14.5.4.1.3. Staphylococcus aureus test
14.5.4.1.4. Legionella pneumophila test
14.5.4.1.5. E. coli Latex test
14.5.4.1.6. Others
14.5.4.2. Kuwait Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
14.5.4.2.1. Pneumococcal infection
14.5.4.2.2. Hemophilus influenzae type b (Hib)
14.5.4.2.3. Rubella
14.5.4.2.4. Others
14.5.4.3. Kuwait Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
14.5.4.3.1. Hospitals
14.5.4.3.2. Diagnostic Centers
14.5.4.3.3. Specialty Clinics
14.5.4.3.4. Others
14.5.5. South Africa
14.5.5.1. South Africa Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Test Type
14.5.5.1.1. Bacterial Antigen test
14.5.5.1.2. Blood and Serum test
14.5.5.1.3. Staphylococcus aureus test
14.5.5.1.4. Legionella pneumophila test
14.5.5.1.5. E. coli Latex test
14.5.5.1.6. Others
14.5.5.2. South Africa Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
14.5.5.2.1. Pneumococcal infection
14.5.5.2.2. Hemophilus influenzae type b (Hib)
14.5.5.2.3. Rubella
14.5.5.2.4. Others
14.5.5.3. South Africa Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.5.3.1. Hospitals
14.5.5.3.2. Diagnostic Centers
14.5.5.3.3. Specialty Clinics
14.5.5.3.4. Others
14.5.6. Rest of Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Latex
Agglutination Test Kits Market Revenue (US$ Mn) and Forecasts, By Test Type
14.5.6.1.1. Bacterial Antigen test
14.5.6.1.2. Blood and Serum test
14.5.6.1.3. Staphylococcus aureus test
14.5.6.1.4. Legionella pneumophila test
14.5.6.1.5. E. coli Latex test
14.5.6.1.6. Others
14.5.6.2. Rest of Middle East & Africa Latex
Agglutination Test Kits Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.5.6.2.1. Pneumococcal infection
14.5.6.2.2. Hemophilus influenzae type b (Hib)
14.5.6.2.3. Rubella
14.5.6.2.4. Others
14.5.6.3. Rest of Middle East & Africa Latex
Agglutination Test Kits Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.6.3.1. Hospitals
14.5.6.3.2. Diagnostic Centers
14.5.6.3.3. Specialty Clinics
14.5.6.3.4. Others
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By Test Type
14.6.3. By Disease Indication
14.6.4. By End Users
15. Latin America Latex Agglutination Test Kits
Market Analysis and Forecasts, 2022 – 2030
15.1. Overview
15.1.1. Latin America Latex Agglutination Test Kits
Market Revenue (US$ Mn)
15.2. Latin America Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Test Type
15.2.1. Bacterial Antigen test
15.2.2. Blood and Serum test
15.2.3. Staphylococcus aureus test
15.2.4. Legionella pneumophila test
15.2.5. E. coli Latex test
15.2.6. Others
15.3. Latin America Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
15.3.1. Pneumococcal infection
15.3.2. Hemophilus influenzae type b (Hib)
15.3.3. Rubella
15.3.4. Others
15.4. Latin America Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By End Users
15.4.1. Hospitals
15.4.2. Diagnostic Centers
15.4.3. Specialty Clinics
15.4.4. Others
15.5. Latin America Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Test Type
15.5.1.1.1. Bacterial Antigen test
15.5.1.1.2. Blood and Serum test
15.5.1.1.3. Staphylococcus aureus test
15.5.1.1.4. Legionella pneumophila test
15.5.1.1.5. E. coli Latex test
15.5.1.1.6. Others
15.5.1.2. Brazil Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
15.5.1.2.1. Pneumococcal infection
15.5.1.2.2. Hemophilus influenzae type b (Hib)
15.5.1.2.3. Rubella
15.5.1.2.4. Others
15.5.1.3. Brazil Latex Agglutination Test Kits Market
Revenue (US$ Mn) and Forecasts, By End Users
15.5.1.3.1. Hospitals
15.5.1.3.2. Diagnostic Centers
15.5.1.3.3. Specialty Clinics
15.5.1.3.4. Others
15.5.2. Argentina
15.5.2.1. Argentina Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Test Type
15.5.2.1.1. Bacterial Antigen test
15.5.2.1.2. Blood and Serum test
15.5.2.1.3. Staphylococcus aureus test
15.5.2.1.4. Legionella pneumophila test
15.5.2.1.5. E. coli Latex test
15.5.2.1.6. Others
15.5.2.2. Argentina Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
15.5.2.2.1. Pneumococcal infection
15.5.2.2.2. Hemophilus influenzae type b (Hib)
15.5.2.2.3. Rubella
15.5.2.2.4. Others
15.5.2.3. Argentina Latex Agglutination Test Kits
Market Revenue (US$ Mn) and Forecasts, By End Users
15.5.2.3.1. Hospitals
15.5.2.3.2. Diagnostic Centers
15.5.2.3.3. Specialty Clinics
15.5.2.3.4. Others
15.5.3. Rest of Latin America
15.5.3.1. Rest of Latin America Latex Agglutination
Test Kits Market Revenue (US$ Mn) and Forecasts, By Test Type
15.5.3.1.1. Bacterial Antigen test
15.5.3.1.2. Blood and Serum test
15.5.3.1.3. Staphylococcus aureus test
15.5.3.1.4. Legionella pneumophila test
15.5.3.1.5. E. coli Latex test
15.5.3.1.6. Others
15.5.3.2. Rest of Latin America Latex Agglutination
Test Kits Market Revenue (US$ Mn) and Forecasts, By Disease Indication
15.5.3.2.1. Pneumococcal infection
15.5.3.2.2. Hemophilus influenzae type b (Hib)
15.5.3.2.3. Rubella
15.5.3.2.4. Others
15.5.3.3. Rest of Latin America Latex Agglutination
Test Kits Market Revenue (US$ Mn) and Forecasts, By End Users
15.5.3.3.1. Hospitals
15.5.3.3.2. Diagnostic Centers
15.5.3.3.3. Specialty Clinics
15.5.3.3.4. Others
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Test Type
15.6.3. By Disease Indication
15.6.4. By End Users
16. Competitive Benchmarking
16.1. Brand Benchmarking
16.2. Market Share Analysis, 2021
16.3. Global Presence and Growth Strategies
16.3.1. Mergers and Acquisitions
16.3.2. Product Launches
16.3.3. Investments Trends
16.3.4. R&D Initiatives
17. Player Profiles
17.1. Alpha Laboratories
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. Arlington Scientific, Inc
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. Atlas Medical GmbH
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. Bio-Rad Laboratories, Inc
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5. Biotec
17.5.1. Company Details
17.5.2. Company Overview
17.5.3. Product Offerings
17.5.4. Key Developments
17.5.5. Financial Analysis
17.5.6. SWOT Analysis
17.5.7. Business Strategies
17.6. Hardy Diagnostics
17.6.1. Company Details
17.6.2. Company Overview
17.6.3. Product Offerings
17.6.4. Key Developments
17.6.5. Financial Analysis
17.6.6. SWOT Analysis
17.6.7. Business Strategies
17.7. Henry Schein, Inc
17.7.1. Company Details
17.7.2. Company Overview
17.7.3. Product Offerings
17.7.4. Key Developments
17.7.5. Financial Analysis
17.7.6. SWOT Analysis
17.7.7. Business Strategies
17.8. HiMedia Laboratories
17.8.1. Company Details
17.8.2. Company Overview
17.8.3. Product Offerings
17.8.4. Key Developments
17.8.5. Financial Analysis
17.8.6. SWOT Analysis
17.8.7. Business Strategies
17.9. Lab M Limited
17.9.1. Company Details
17.9.2. Company Overview
17.9.3. Product Offerings
17.9.4. Key Developments
17.9.5. Financial Analysis
17.9.6. SWOT Analysis
17.9.7. Business Strategies
17.10. Lorne Laboratories Limited
17.10.1. Company Details
17.10.2. Company Overview
17.10.3. Product Offerings
17.10.4. Key Developments
17.10.5. Financial Analysis
17.10.6. SWOT Analysis
17.10.7. Business Strategies
17.11. Microgen
17.11.1. Company Details
17.11.2. Company Overview
17.11.3. Product Offerings
17.11.4. Key Developments
17.11.5. Financial Analysis
17.11.6. SWOT Analysis
17.11.7. Business Strategies
17.12. Ngaio Diagnostics
17.12.1. Company Details
17.12.2. Company Overview
17.12.3. Product Offerings
17.12.4. Key Developments
17.12.5. Financial Analysis
17.12.6. SWOT Analysis
17.12.7. Business Strategies
17.13. Plasmatec
17.13.1. Company Details
17.13.2. Company Overview
17.13.3. Product Offerings
17.13.4. Key Developments
17.13.5. Financial Analysis
17.13.6. SWOT Analysis
17.13.7. Business Strategies
17.14. Pro Lab Diagnostics Inc.
17.14.1. Company Details
17.14.2. Company Overview
17.14.3. Product Offerings
17.14.4. Key Developments
17.14.5. Financial Analysis
17.14.6. SWOT Analysis
17.14.7. Business Strategies
17.15. Thermo Fisher Scientific Inc
17.15.1. Company Details
17.15.2. Company Overview
17.15.3. Product Offerings
17.15.4. Key Developments
17.15.5. Financial Analysis
17.15.6. SWOT Analysis
17.15.7. Business Strategies
17.16. Torax Biosciences Limited
17.16.1. Company Details
17.16.2. Company Overview
17.16.3. Product Offerings
17.16.4. Key Developments
17.16.5. Financial Analysis
17.16.6. SWOT Analysis
17.16.7. Business Strategies
17.17. Trafalgar Scientific Ltd
17.17.1. Company Details
17.17.2. Company Overview
17.17.3. Product Offerings
17.17.4. Key Developments
17.17.5. Financial Analysis
17.17.6. SWOT Analysis
17.17.7. Business Strategies
17.18. Other Market Participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.